Merck’s Lipfendra is the first FDA-approved pill in the class of cholesterol-lowering drugs called PCSK9 inhibitors. While peptides are typically injected, Lipfendra is a macrocyclic peptide designed for formulation as an oral drug.
The post Merck Pill Becomes First Oral Option in Growing Class of Cholesterol-Lowering Drugs appeared first on MedCity News.
